WO2025262600 - CRYSTALLINE FORM OF VIBEGRON HEMIHYDRATE
National phase entry is expected:
Publication Number
WO/2025/262600
Publication Date
26.12.2025
International Application No.
PCT/IB2025/056180
International Filing Date
17.06.2025
Title **
[English]
CRYSTALLINE FORM OF VIBEGRON HEMIHYDRATE
[French]
FORME CRISTALLINE D'HÉMIHYDRATE DE VIBÉGRON
Applicants **
UROVANT SCIENCES GMBH
Inventors
ZHANG, Haitao
Priority Data
63/660,955
17.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2227 | |
| EPO | Filing, Examination, Granting | 11333 | |
| Japan | Filing, Examination, Granting | 2359 | |
| South Korea | Filing, Examination, Granting | 2430 | |
| USA | Filing, Examination, Granting | 7340 |
Total:
25,689
Contact Us
Abstract[English]
Described herein is a crystalline form of a hemihydrate of the β-3 adrenergic receptor agonist vibegron. The disclosure also relates to preparations of the crystalline form, pharmaceutical compositions thereof, methods of making the crystalline form, and methods of using the crystalline form in the treatment of overactive bladder.[French]
L'invention concerne une forme cristalline d'un hémihydrate du vibégron agoniste du récepteur β-3 adrénergique. L'invention concerne également des préparations de la forme cristalline, des compositions pharmaceutiques de celles-ci, des procédés de fabrication de la forme cristalline, ainsi que des procédés d'utilisation de la forme cristalline dans le traitement de la vessie hyperactive.